Option, License & Collaboration Agreement was Assembly Biosciences’s largest revenue line in fiscal 2025, bringing in $37.30M of $72.30M (52%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2021 | FY 2024 | FY 2025 |
|---|---|---|---|
| Hpi Program License | — | $35.00M | |
| Option, License & Collaboration Agreement | $28.50M | $37.30M | |
| Beigene Agreement | — | — | |
| Total | $28.50M | $72.30M |
Assembly Biosciences brought in $72.30M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. Assembly Biosciences regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $28.50M. Option, License & Collaboration Agreement was the largest at $37.30M (51.6%), ahead of Hpi Program License at $35.00M (48.4%).
Assembly Biosciences began breaking out Hpi Program License in fiscal 2025, when it brought in $35.00M.
Assembly Biosciences (ASMB) reports its revenue by collaborative arrangement and arrangement other than collaborative. In fiscal 2025, Option, License & Collaboration Agreement was its largest revenue line, bringing in $37.30M (51.6% of the total), followed by Hpi Program License at $35.00M (48.4%).
Option, License & Collaboration Agreement was Assembly Biosciences' largest revenue line in fiscal 2025, bringing in $37.30M, or 51.6% of the $72.30M total across its two revenue lines.
Every figure comes from Assembly Biosciences' annual financial filings, as reported. Each line keeps the name Assembly Biosciences gives it, and years follow its fiscal calendar.
Assembly Biosciences' revenue by collaborative arrangement and arrangement other than collaborative goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.